Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.

Literature DB >> 1222395

Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.

R C Kane, M H Cohen, L E Broder, M I Bull, P J Creaven, B E Fossieck.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Emetine

Year: 1975 PMID： 1222395

Source DB: PubMed Journal: Cancer Chemother Rep ISSN： 0069-0112

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines.

Authors: Emmanuel S Akinboye; Zebalda D Bamji; Bernard Kwabi-Addo; David Ejeh; Robert L Copeland; Samuel R Denmeade; Oladapo Bakare
Journal: Bioorg Med Chem Date: 2015-07-04 Impact factor: 3.641

2. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Authors: Christian K Hirt; Tijmen H Booij; Linda Grob; Patrik Simmler; Nora C Toussaint; David Keller; Doreen Taube; Vanessa Ludwig; Alexander Goryachkin; Chantal Pauli; Daniela Lenggenhager; Daniel J Stekhoven; Christian U Stirnimann; Katharina Endhardt; Femke Ringnalda; Lukas Villiger; Alexander Siebenhüner; Sofia Karkampouna; Marta De Menna; Janette Beshay; Hagen Klett; Marianna Kruithof-de Julio; Julia Schüler; Gerald Schwank
Journal: Cell Genom Date: 2022-02

3. A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma.

Authors: Christina V Angeles; Ana Velez; Tomoyo Okada; Samuel Singer; Jordan Rios; Bernadette Laxa; David Shum; Penelope D Ruiz; Yawei Shen; Irina Ostrovnaya; Rodrigo Gularte-Mérida; Benjamin A Nacev; Mark A Dickson; Hakim Djaballah
Journal: Clin Cancer Res Date: 2021-10-19 Impact factor: 13.801

Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.

1. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines.

2. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

3. A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma.

4. Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.

5. Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt/β‑catenin signaling.

6. Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells.

7. Recent developments on potential new applications of emetine as anti-cancer agent.